The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well-controlled Type 2 (non-insulin-dependent) diabetes mellitus: dependency on acutely established hyperglycaemia

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Diabetologia

• Publication date

  1989-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00297450PMID 2693165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus.

  2009cited by this paper
• C-peptide and proinsulin after oral glucose.

  2009cited by this paper
• Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes

  1989cited by this paper
• The beta-cell response to glucagon and mixed meal stimulation in non-insulin dependent diabetes.

  1988cited by this paper
• Quantitative study of insulin secretion and clearance in normal and obese subjects.

  1988cited by this paper
• Insulin Requirement in Non‐insulin‐dependent Diabetes Mellitus: Relation to Simple Tests of Islet B‐cell Function and Insulin Sensitivity

  1988cited by this paper
• Postexercise dose-response relationship between plasma glucose and insulin secretion.

  1988cited by this paper
• Effect of physical exercise on sensitivity and responsiveness to insulin in humans.

  1988cited by this paper
• Insulin Secretion and Clearance: Comparison After Oral and Intravenous Glucose

  1987cited by this paper
• Relationship of islet function to insulin action in human obesity.

  1987cited by this paper
• Plasma and urinary C-peptide in the classification of adult diabetics.

  1986cited by this paper
• secondary Failure to Treatment with Oral Antidiabetic Agents in Non-insulin-dependent Diabetes

  1986cited by this paper
• Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

  1986cited by this paper
• C-peptide determination in the choice of treatment in diabetes mellitus.

  1985cited by this paper
• A comparison of serum C-peptide response to intravenous glucagon, and urine C-peptide, as indexes of insulin dependence.

  1985cited by this paper
• The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus

  1985cited by this paper
• Europium as a label in time-resolved immunofluorometric assays.

  1984cited by this paper
• C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations

  1984cited by this paper
• Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

  1984influential reference
• Splanchnic and renal metabolism of insulin in human subjects: a dose-response study.

  1983cited by this paper
• Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion.

  1983cited by this paper
• Therapeutic effect of tolbutamide in non-insulin dependent diabetes mellitus (NIDDM). Relation to beta-cell function.

  1982cited by this paper
• Isoproterenol-stimulated C-peptide and insulin secretion in diabetic and nonobese normal subjects: decreased hepatic extraction of endogenous insulin in diabetes.

  1980cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper
• C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus

  1977cited by this paper
• Specific and direct radioimmunoassay for human proinsulin in serum

  1977cited by this paper
• Radioimmunological determination of human C-peptide in serum

  1975cited by this paper
• A comparative study on the metabolism of human insulin and porcine proinsulin in man.

  1973cited by this paper
• Wick Chromatography for Rapid and Reliable Immunoassay of Insulin, Glucagon and Growth Hormone

  1968cited by this paper

• C-peptide in Precision Diabetes Care and Beyond: A Comprehensive Review

  2026cites this paper
• A Cross-sectional Study to Assess Beta-Cell Function in Individuals with Recently Diagnosed Young-Onset Type 2 Diabetes Mellitus and Its’ Complications

  2022cites this paper
• The clinical utility of C-peptide measurement in the care of patients with diabetes

  2013cites this paper
• CLINICAL ASPECTS ON GLUCOSE-LOWERING THERAPIES IN TYPE 2 DIABETES

  2012cites this paper
• Variation of Fasting Serum C-Peptide Level After Admission in Japanese Patients with Type 2 Diabetes Mellitus

  2009cites this paper
• Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.

  2005cites this paper
• A simple clinical approach to discriminate between “true” and “pseudo” secondary failure to oral hypoglycaemic agents

  2004cites this paper
• A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility

  2000cites this paper
• Elevated Plasma Proinsulin/Insulin Ratio is a Marker of Reduced Insulin Secretory Capacity in Healthy Young Men

  1999cites this paper
• Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs

  1997cites this paper
• Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement.

  1996cites this paper
• Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.

  1996cites this paper
• Exhaustion of blood glucose response and enhancement of insulin response after repeated glucagon injections in type-2 diabetes: potentiation by progressive hyperglycemia.

  1996cites this paper
• Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.

  1996cites this paper
• Insulin and C-peptide secretion in non-insulin-dependent diabetes mellitus and its response to dietary therapy.

  1995cites this paper
• Islet cell antibodies are associated withβ-cell failure also in obese adult onset diabetic patients

  1994cites this paper
• C-Peptide in NIDDM: Follow-up for 4-6 yr

  1993cites this paper
• The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes

  1992cites this paper
• The Effect of Chronic Hyperglycaemia on the Islet B‐cell Responsiveness in Newly Diagnosed Type 2 Diabetes

  1992cites this paper
• C-peptide used in the estimation of islet beta-cell function in diabetes.

  1992cites this paper
• Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.

  1992cites this paper
• C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment.

  1992cites this paper
• Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation. A comparison between insulin and C-peptide to measure insulin secretion.

  1992cites this paper
• The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus.

  1991cites this paper